Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Non Operating Income (2020 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Non Operating Income for 6 consecutive years, with $30000.0 as the latest value for Q3 2025.

  • For Q3 2025, Non Operating Income fell 92.59% year-over-year to $30000.0; the TTM value through Sep 2025 reached $1.4 million, up 122.67%, while the annual FY2024 figure was $571000.0, 59.5% up from the prior year.
  • Non Operating Income hit $30000.0 in Q3 2025 for Cyclerion Therapeutics, down from $1.3 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.3 million in Q2 2025 and bottomed at -$6000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $137526.3, with a median of $62000.0 recorded in 2023.
  • Year-over-year, Non Operating Income crashed 105.38% in 2021 and then soared 13300.0% in 2022.
  • Cyclerion Therapeutics' Non Operating Income stood at -$1000.0 in 2021, then skyrocketed by 13300.0% to $132000.0 in 2022, then decreased by 23.48% to $101000.0 in 2023, then tumbled by 72.28% to $28000.0 in 2024, then grew by 7.14% to $30000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $30000.0, $1.3 million, and $28000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.